Search Results 901-910 of 17096 for monoclonal antibody

1. Hematology - Clinical trials

   The purpose of this study is to determine the cellular and mechanistic basis of bone marrow hematopoietic dysfunction in untreated Monoclonal B Cell ...

2. A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   ... antibody. Eastern Cooperative Oncology Group (ECOG) performance status ... monoclonal antibodies ≤ 14 days prior to registration. Patients who have ...

3. ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer - Mayo Clinic

   Prior antibody treatment for cancer must have been ... Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal ...

4. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study - Mayo Clinic

   to fistula formation. - Participants must not have received investigational agents or monoclonal antibodies (except Food and Drug Administration [FDA] ...

5. Seroprevalence Study of Pre-existing Immunity for Adenovirus-associated Virus Vector in MYBPC3-associated Hypertrophic Cardiomyopathy - Mayo Clinic

   Currently receiving systemic immunosuppressive therapy, cytotoxic chemotherapy, immunoglobulin therapy, or monoclonal antibody therapy. History of ...

6. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.

7. A Study Using Clofarabine and Cytarabine in Treating Children with Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia - Mayo Clinic

   At least 14 days since prior monoclonal antibody therapy; No more than 1 prior autologous or allogeneic hematopoietic stem cell transplantation. No evidence ...

8. Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) - Mayo Clinic

   No history of severe allergic reactions to monoclonal antibodies. Female ... Hepatitis C as indicated by anti-hepatitis C antibody positivity; if a participant is ...

9. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   ... monoclonal antibodies or Chimeric Antigen Receptor (CAR) T-cell therapy; Patients with a chronic condition requiring the use of systemic corticosteroids at a ...

10. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) - Mayo Clinic

    Prior monoclonal antibody within 4 weeks prior to study Day 1 (2 weeks for RS participants) or who has not recovered (i.e. ≤ Grade 1 or at baseline) from ...